Open access
Oct 2026
Beyond venetoclax and azacitidine: CD70-targeted triplet therapy in acute myeloid leukemia.
Not available.
S. Garciaz
· Haematologica · 0 citations
We have 2 of 93 papers
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
Open access
Sep 2026
Comparison of venetoclax and azacitidine versus a cytarabine-based treatment for patients with acute myeloid leukaemia in first relapse after chemotherapy. A real-world study of the DATAML-IPC-AURAML consortium.
Complete remission (CR) rates for patients with acute myeloid leukaemia (AML) treated with intensive chemotherapy (IC) have increasingly improved. Yet, relapse remains a concern with a dismal prognosis. In this report, results are presented of a retrospective analysis comparing salvage therapy based on intermediate (I)...
P. Dumas, S. Bertoli, Emilie Bérard et al.
· British Journal of Haematolo... · 0 citations